NKGen Biotech, Inc. (NKGN)

NASDAQ: NKGN · Real-Time Price · USD

0.570

+0.122 (27.12%)

At close: Feb 21, 2025, 4:00 PM

0.500

-0.070 (-12.20%)

After-hours: Feb 21, 2025, 7:59 PM EST

NKGen Biotech Employees

NKGen Biotech had 63 employees as of December 31, 2023.

Employees

63

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

-$1,400,841

Market Cap

25.60M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	63	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	440,000
Johnson & Johnson	131,900
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	72,000

Employee Rankings

NKGN News

1 day ago - NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - GlobeNewsWire
3 days ago - NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site - GlobeNewsWire
9 days ago - NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer's Disease - GlobeNewsWire
10 days ago - NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer's Disease - GlobeNewsWire
2 months ago - NKGen Biotech Selected as Stalking Horse Bidder for NKMax - GlobeNewsWire
3 months ago - NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel - GlobeNewsWire
4 months ago - NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
4 months ago - NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024) - GlobeNewsWire